Exenatide IR
Byetta
Half-life
2.4 hr
Time to Peak
2.1 hr
Steady State
~1 days
Dose Range
5–10 mcg
Frequency
Twice daily
Overview
Twice-daily injectable GLP-1 receptor agonist for type 2 diabetes. Must be injected within 60 minutes before morning and evening meals. First GLP-1 RA approved (2005).
Mechanism of Action
GLP-1 receptor agonist based on synthetic exendin-4 (53% homology to native GLP-1). Short-acting formulation with primarily post-prandial glucose lowering.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Subcutaneous (SubQ) | 5–10 mcg | 2.4 hr | 2.1 hr | Twice daily |
Storage & Handling
2-8C — Refrigerate before first use. After first use: room temp (up to 25C) for up to 30 days. Do not freeze.
Used in Regimens
Exenatide IR is not currently part of any catalog regimen.
Data Sources
- FDA Label Byetta FDA Prescribing Information
Related Tools
Track Exenatide IR with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.